Rising obesity rates worldwide have socio-economic ramifications. While genetics, diet, and lack of exercise are major contributors to obesity, environmental factors may enhance susceptibility through disruption of hormone homeostasis and metabolic processes. The obesogen hypothesis contends that chemical exposure early in development may enhance adipocyte differentiation, thereby increasing the number of adipocytes and predisposing for obesity and metabolic disease. We previously developed a primary human adipose stem cell (hASC) assay to evaluate the effect of environmental chemicals on PPARG-dependent adipogenesis. Here, the assay was modified to determine the effects of chemicals on the glucocorticoid receptor (GR) pathway. In differentiation cocktail lacking the glucocorticoid agonist dexamethasone (DEX), hASCs do not differentiate into adipocytes. In the presence of GR agonists, adipocyte maturation was observed using phenotypic makers for lipid accumulation, adipokine secretion, and expression of key genes. To evaluate the role of environmental compounds on adipocyte differentiation, progenitor cells were treated with 19 prioritized compounds previously identified by ToxPi as having GR-dependent bioactivity, and multiplexed assays were used to confirm a GR-dependent mode of action. Five chemicals were found to be strong agonists. The assay was also modified to evaluate GR-antagonists, and 8/10 of the hypothesized antagonists inhibited adipogenesis. The in vitro bioactivity data was put into context with extrapolated human steady state concentrations (Css) and clinical exposure data (Cmax). These data support using a human adipose-derived stem cell differentiation assay to test the potential of chemicals to alter human GR-dependent adipogenesis.
Introduction
The global rise in obesity across all age groups is a growing crisis from both a health and an economic standpoint. Of greatest concern is the rise in childhood obesity, which has tripled since 1980 (Kumar and Kelly, 2017) . As of 2016, one in three children is considered overweight or obese (Kumar and Kelly, 2017) . Because adipose tissue continues to develop through adolescence, and the number of adipocytes is determined by age eighteen, childhood obesity predisposes these individuals to a lifetime of health risks, as well as susceptibility to changes in diet and lifestyle (Spalding et al., 2008) . Although the two major risk factors for obesity include excess caloric intake and a sedentary lifestyle, there are growing concerns that other risk factors such as environmental chemicals, stress, nutrient intake, and the gut microbiome may play a role (Thayer et al., 2012) . The so-called "obesogen hypothesis" was first proposed by Grun and Blumberg in 2006 and suggests that exposure to xenobiotics may alter the development of adipose tissue early in life (Grun and Blumberg, 2006) .
Until recently, adipose tissue was largely considered to be an inert tissue that was necessary for energy storage. However, it has become increasingly clear that adipose tissue is a highly active endocrine organ capable of secreting biologically active molecules, including hormones, growth factors, and cytokines (Coelho et al., 2013) . There is growing public and scientific concern that chemical exposure may disrupt these endocrine processes and thereby promote a variety of human health effects ranging from metabolic disorders to reproductive effects to cancer (Diamanti-Kandarakis et al., 2009) . Adipogenesis is a tightly controlled program of gene expression that drives the differentiation of committed pre-adipocytes to mature functional adipocytes ( Fig. 1 ) (Moseti et al., 2016) . The glucocorticoid receptor (GR), encoded by the Nuclear Receptor Subfamily 3 Group C Member 1 gene (NR3C1), potentiates early commitment of adipose progenitors by modulating key CCAAT/enhancer binding protein (C/EBP) function, in turn inducing expression of peroxisome proliferator activated receptor γ (PPARG) (Farmer, 2006) . PPARG is considered the master regulator of adipogenesis, driving a transcriptional program that turns on adipogenic gene expression and promotes maturation of the adipocyte (Farmer, 2006) . Terminal differentiation is evidenced by canonical phenotypic characteristics of the mature adipocyte, including lipid synthesis and accumulation, insulin activity, and secretion of adipokines (Symonds, 2012) .
Given the emphasis in the regulatory, legislative, and scientific communities to move toward in vitro alternatives from traditional in-life animal toxicity studies, it is important that cell-based assays are developed that can faithfully assess biological responses to potential toxicants both in terms of phenotypic outcome and concentration-response (Yoon et al., 2016; McMullen et al., 2018) . While high throughput screens such as ToxCast and Tox21 are valuable for evaluating bioactivity and may be useful for identifying key molecular initiating events, there is a need to test potentially active chemicals in systems with more fidelity to the in vivo system. ToxCast and Tox21 assays probe biomarkers of several pathways important to adipogenesis, including PPARG and GR. However, to date, there is no "gold standard" assay for testing the potential effects of exogenous chemicals on adipocyte differentiation, either in vivo or in vitro. Current technologies primarily focus on non-human in vivo alternative and in vitro methods, including zebrafish and the mouse fibroblast (3T3-L1) in vitro model (Sargis et al., 2010; Lyssimachou et al., 2015; den Broeder et al., 2017; Park et al., 2017) . We recently developed a novel human adipose-derived stem cell (hASC) assay to assess the adipogenic effects of endocrine disrupting chemicals (EDCs) (Foley et al., 2015; Foley et al., 2017) . Based on the current knowledge of the key biological pathways that drive adipocyte differentiation, the assay used a hormone cocktail of PPARG, GR, and C/EBP agonists and insulin to drive differentiation of hASCs to a fully mature phenotype capable of lipid accumulation and adipokine secretion. This assay was found to be useful for evaluating chemical-induced adipogenesis via activation of PPARG (Foley et al., 2017) .
In this paper, we describe further development and application of the human adipogenesis assay to evaluate the role of chemicals affecting the GR pathway in adipocyte maturation. To prioritize compounds for testing, the ToxPi analysis tool, which combines assay results from the ToxCast/Tox21 GR binding, agonist and antagonist transcriptional reporter assays to give each chemical a bioactivity score, was used to rank chemicals according to their potential GR activity . The top-ranking chemicals for GR activity were tested in our phenotypic adipogenesis assay. To evaluate GR-mediated activity, the published human adipose-derived stem cell assay (Foley et al., 2017) was modified by removing the synthetic glucocorticoid dexamethasone (DEX), which allowed the determination of whether any of the suspected glucocorticoid agonists could surrogate for DEX. Assay endpoints were designed to assess critical steps along the adipogenesis cascade, including adipogenic gene expression, lipid accumulation, and adipokine secretion, as well as chemical cytotoxicity (Fig. 1 ). These endpoints were streamlined into a single plate format, such that all endpoints could be tested within a single well in a concentration-dependent manner. In addition, the assay was leveraged to assess GR antagonism, making it a highly tractable tool for determining the effects of candidate chemicals on GR-mediated adipogenesis. These studies demonstrate the use of a biology-driven approach to develop a species-relevant phenotypic assay that can be used to further test prioritized chemicals identified from in vitro high-throughput screening approaches.
Materials and methods

Cell culture
Human subcutaneous adipose-derived stem cells were obtained at passage 2 from a pooled donor super lot (SL0055, Zen-Bio, Research Triangle Park, NC). The donor pool consisted of 10 non-diabetic, nonsmoking females with a mean age of 46.7 years and mean BMI of 26.8. Cells were maintained in high glucose Dulbecco's Modified Eagle's Medium with L-glutamine and sodium pyruvate (Thermo Scientific, Waltham, MA) supplemented with 10% mesenchymal stem cell-fetal bovine serum (LifeTech, Carlsbad, CA), 100 U/mL penicillin, 100 μg/ mL streptomycin, and 0.25 μg/mL Amphotericin B (Corning, Corning, NY) at 5% CO2 in a 37°C humidified chamber (maintenance media). Fig. 1 . Development of a multiplexed fit-for-purpose assay for GR-mediated adipogenesis. In vivo, adipogenesis occurs through a series of well-defined molecular events. An adipogenic stimulator activates the glucocorticoid receptor, leading to transcriptional activation of CEBPD and the downstream signaling cascade, including expression of PPARG, which is the master regulator of adipocyte differentiation. To fully differentiate, a committed preadipocyte undergoes activation of adipogenic gene expression, followed by terminal differentiation, lipid accumulation, and ultimately adipokine secretion. To develop an in vitro model of adipogenesis, hASCs are treated with a cocktail that can induce adipogenesis (dexamethasone, rosiglitazone, insulin, and IBMX). To determine GR-mediated adipogenesis, the hASCs are primed with a cocktail (rosiglitazone, insulin, IBMX) that is necessary but not sufficient for adipogenesis in the absence of a GR agonist (*dexamethasone replaced or augmented with ToxCast prioritized compounds). The cells are simultaneously treated in test compound and differentiation is phenotypically assessed in a single well using three distinct phenotypic endpoints: adipogenic gene activation (FABP4 protein expression), lipid accumulation (AdipoRed neutral lipid staining), and adipokine secretion (adiponectin secretion). 
Chemicals and reagents
Triamcinolone (TC): CASRN 124-94-7, > 99% purity; Mifepristone (MIF): CASRN 84371-65-3, > 99% purity; Prednisone (PRED): CASRN 53-03-2, > 99% purity; Cyproterone Acetate (CPA): CASRN 427-51-0, > 99% purity; and Norethindrone (NET): CASRN 68-22-4, > 99%; Dexamethasone: CASRN 50-02-2, > 99% purity and Rosiglitazone: CASRN 122320-73-4, > 99% purity, were purchased from Selleck Chemicals LLC (Houston, TX). 11-epihydrocortisone: CASRN 566-35-8, Toronto Research chemicals, > 99% purity was purchased from Toronto Research Chemicals (Toronto, Ontario). Dexamethasone Sodium Phosphate (DEX): CASRN 2392-39-4, ≥98% purity; Melengestrol Acetate (MGA): CASRN 2919-66-6, > 99% purity; 17alpha-hydroxyprogesterone (17OHP): CASRN 68-96-2, > 99% purity; Thiocarbazide (THI): CASRN 2231-57-4, 98% purity; Dicamba (DIC): CASRN 1918-00-9, > 99% purity; Norgestrel (NOR): CASRN 797-63-7, > 99% purity; Hydroxyprogesterone Caproate (OHPC): 630-56-8, USP reference standard; 3,5,3′-triiodothyronine (T3): CASRN 6893-02-3, > 99% purity; Corticosterone (CORT): CASRN 50-22-6, > 99% purity; Cyclohexylphenylketone (CPK): CASRN 712-50-5, 98% purity; Diethyl Sulfate (DES): CASRN 64-67-5, 98% purity; Bis(2-ethylhexyl) Tetrabromophthalate (TBPH): CASRN 26040-51-7, 95% purity; Spironolactone (SPI): CASRN 52-01-7, USP reference standard; Equilin (EQU): CASRN 474-86-2, > 99% purity; Tolylfluanid (TF): CASRN 731-27-1, > 99% purity; GW9662: CASRN 22978-25-2, ≥98% purity; and Hydrocortisone: CASRN 50-23-7, ≥98% purity; 3-isobutyl-1-methylxanthine (IBMX): CASRN 28822-58-4, > 99% purity and Human Insulin Solution: CASRN 11061-68-0, were purchased from Sigma-Aldrich (St. Louis, MO). PF915275: CASRN 857290-04-1, Tocris, ≥98% purity, was purchased from Bio-Techne (Minneapolis, MN). Chemical purities are per supplier's specification sheets. All treatment compounds were dissolved in 100% DMSO to stock concentrations of 100 mM. The medium components dexamethasone and rosiglitazone were dissolved in DMSO to 10 mM stocks, and IBMX was dissolved in DMSO to 200 mM. PF915275 was dissolved in DMSO to a 1 mM stock.
Relative lipid accumulation
The neural lipid stain AdipoRed (Lonza, Basel, Switzerland) was diluted 1:40 and the nuclear dye Hoechst 33342 (Sgima-Aldrich, St. Louis, MO) was diluted to 5 μg/mL in a 4% paraformaldehyde solution. Cells were simultaneously fixed and stained in this solution for 30 min. The fluorescence intensities of AdipoRed (Ex. 485 nm, Em. 590 nm) and Hoechst 33342 (Ex. 320, Em. 460 nm) were detected using the 
Lactate dehydrogenase activity
Acute cytotoxicity of the control and treatment conditions was assessed using a colorimetric lactate dehydrogenase (LDH) activity assay (Roche Diagnostics GmbH, Mannheim, Germany). The kit was performed according to the manufacturer's protocol. Supernatants were collected from all wells after the initial 48 hour treatment and stored at −20°C until the assay was performed. Reagents and supernatants were allowed to thaw to room temperature away from light prior to use. Supernatant samples and the LDH reagent mixture were combined in equal volumes and allowed to incubate at room temperature away from light for 20 min. STOP solution was added to each sample at 1:5 to halt the reaction. The level of acute cytotoxicity was detected as a colorimetric absorbance value using the FlexStation 3 Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, CA). LDH values were averaged across the technical replicates and normalized to vehicle control wells to determine fold-change values across test plates.
Cytotoxicity analysis
Chronic cytotoxicity was assessed at the end of the treatment period by counting the number of cells in a portion of each well. Plates were imaged using the 20× air immersion objective on the Opera Phenix High-Content Screening System (Perkin Elmer, Waltham, MA), and image analysis was performed on Harmony 4.1 High Content Imaging and Analysis Software (Perkin Elmer, Waltham, MA). Hoechst-stained nuclei were identified using a blue laser (excitation 405 nm, emission 435-480 nm), and 9 central fields were imaged in each well. Counts were refined by excluding Hoechst-labeled objects that lacked the degree of roundness measured in typical healthy ASC nuclei to prevent counting debris or dead cells, and nuclei overlapping the border were also removed. Cell counts were averaged across the technical replicates and normalized to the average vehicle control well counts on a plateby-plate basis.
Glucocorticoid receptor dependence assay
Adipose-derived stem cells were plated as described above. A 9-point half-log concentration response curve was employed for this assay ranging from 100 μM-0.01 μM final concentrations. To determine GR dependence, the cells received either the candidate compound alone or the compound in combination with the GR antagonist mifepristone (RU-486) at a static concentration of 10 μM. Each test compound set included mifepristone only controls as well as a no treatment, no mifepristone vehicle control. Test compound, antagonist, and control treatments were refreshed every 48 h for a total of eight days. At the end of the eight day treatment period, RLA and chronic cytotoxicity were assessed.
Meso scale discovery (MSD) adipokine secretion assay
Supernatants were removed from the treatment wells (which were used to measure RLA and FABP4 expression), and a singleplex electrochemiluminescent ELISA was used to detect GR-dependent adipokine secretion following the eight day treatment period as previously described (Foley et al., 2017) . Briefly, the adiponectin assay (Meso Scale Diagnostics, LLC., K151BXC) was performed according to the J.K. Hartman et al. Toxicology and Applied Pharmacology 355 (2018) 112-126 manufacturer's protocol with three alterations to improve small-volume sensitivity for cell culture applications: 1) undiluted supernatant volume used was 20 μL, 2) primary incubation periods with test sample were increased to 16 h at 4°C, and 3) the linear range of the calibrator standard curve was extended down to 0.00256 ng/mL. The MSD Discovery Workbench software was used to extrapolate raw adiponectin concentrations (ng/mL) from the standard curve using a 4-parameter logistic model with a 1/Y 2 weighting function to enhance low end curve-fitting. Sample values were averaged across the technical and biological replicates and normalized to plate-based vehicle controls and plotted as fold change.
Protein expression
The expression of FABP4 was measured via immunofluorescence. Treated cells were blocked for 1 h in 5% BSA in PBS-T (PBS + 0.2% Tween-20) and subsequently incubated overnight at 4°C with anti-FABP4 primary antibody (Abcam, ab92501) diluted 1:500 in blocking buffer. The cells were washed 3 times for 10 min in PBS-T and incubated with goat anti-rabbit AlexaFluor647 secondary antibody (ThermoFisher Scientific, A32733) and 4′,6-diamidino-2-phenylindole (DAPI, 0.1 μg/mL, ThermoFisher Scientific, D1306) for 1 h at room temperature in the dark. The cells were rinsed and stored in PBS until imaging. The plates were imaged using the OperaPhenix at 20× magnification using the air-objective in non-confocal mode, and the FABP4 positive cells were quantified using cytoplasmic FABP4 intensity using the Harmony software. The percent of FABP4+ cells was determined as the number of FABP4 + nuclei out of total DAPI quantified nuclei (% FABP4 + cells = number of FABP4 + nuclei/total nuclei * 100).
GR antagonist screen
Adipose-derived stem cells were plated as described above. A 10-point half-log concentration response curve was employed for this assay ranging from 100 μM-0.003 μM final concentrations. To determine GR antagonism, the cells were concurrently treated with a 10-point concentration curve of each test compound as well as the known GR agonist dexamethasone at a static concentration of 20 nM. Each test compound set included a dexamethasone only control as well as a no treatment, no dexamethasone vehicle control. Test compound and dexamethasone treatments were refreshed every 48 h for a total of eight days. At the end of the eight day treatment period, RLA and cytotoxicity were assessed as described above.
Statistical analysis
To determine statistical significance across doses, a one-way ANOVA with a Dunnett's multiple comparison test was performed.
To determine a hit in the primary and orthogonal endpoint assays, the normalized values for each chemical for each endpoint were transformed relative to the vehicle and positive controls, 
where y′ is the renormalized value of y (the normalized value for each chemical), and b val & p val are the values of the negative and positive controls, respectively evaluated in the assay. Using y', the area under the curve (AUC) was calculated for each chemical for each concentration curve by integrating a piecewise linear spline across non-cytotoxic concentrations (determined by a > 10% decrease in cell counts below the vehicle control). For calculation of the AUC, the log-transformed concentration was used. Negative AUC values were taken to be zero. The AUC for each chemical and endpoint was rank ordered from largest to smallest to determine bioactivity. Two aggregate AUC scores (one for agonism and one for antagonism) were calculated for each compound to determine whether bioactivity constituted a hit. Aggregate AUC was calculated as the unweighted arithmetic mean of the AUC agonism or antagonism endpoints. Because measured endpoints are renormalized to positive and negative controls, the three contributions to AUC are evenly weighted based on their biological range. This minimizes the impact that technical artifacts such as assay sensitivity and dynamic range contribute to the scoring. Theoretical range for AUC in this assay, based on (i) the positive/negative controls and (ii) the dose range considered is 0 to 4.50. The mean and standard deviation of the aggregate AUC for the least responsive agonists and antagonists was calculated, and any compounds with an AUC greater than three standard deviations above the mean was scored as a hit for agonism or antagonism, respectively. AC 50 values were derived from Hill functions fit to concentration response data using Python, where c is the molar concentration, tp is the top asymptotic limit, ga is the AC 50 , and gw is the Hill coefficient. Models were fit using the scipy.optimize package implementation of least-squares optimization using the Levenberg-Marquardt algorithm (Oliphant, 2007) . Models were constrained so 0 < tp < 1.4 to allow flexibility around the assay theoretical maximum response (i.e., tp = 1) defined by p val.
Estimation of a steady-state concentration in vivo
A literature search was performed in the US National Center for Biotechnology Information's PubMed database (https://www.ncbi. nlm.nih.gov/pubmed) to identify pharmacokinetic data (e.g., peak concentration (Cmax) and total clearance) of compounds (5 agonists/ 8 antagonists) in human. The name of each chemical was used as a keyword, combined with other relevant keywords such as "pharmacokinetics", "clinical trials", and "healthy volunteers", in order to identify pharmacokinetic studies or randomized controlled trials in the form of full publications in English. Cmax and total clearance were identified following various therapeutic doses of prednisone (Sullivan et al., 1976; Schalm et al., 1977; Arancibia et al., 2005) , dexamethasone sodium phosphate (Tsuei et al., 1979; Loew et al., 1986; Varis et al., 2000) , triamcinolone (Mollmann et al., 1985; Derendorf et al., 1995; Argenti et al., 1999) , hydroxyprogesterone caproate (Caritis et al., 2011 ), norethindrone (LeBel et al., 1998 Griffith and Dai, 2004) , cyproterone acetate (Kuhnz et al., 1993; Kuhnz et al., 1997) , norgestrel (Stanczyk, 2003) , mifepristone (Kekkonen et al., 1996; Heikinheimo, 1997; Sarkar, 2002) , spironolactone (Abshagen et al., 1979) in humans. For estimation of a steady-state concentration (Css) of these compounds, the ExpoCast median predictions (mg/kg/ day) was used (Wambaugh et al., 2014; USEPA Chemistry Dashboard, 2017) . Css was determined by the ratio of the dose rate (mg/day for 70 kg-adult) to the sum of all clearances, i.e., total body clearance (Yoon et al., 2014) . Css (M) is obtained from the following equation:
Results
Optimization of an in vitro model for glucocorticoid-receptor mediated human adipogenesis
We previously developed a human adipose stem cell assay fit for the purpose of assessing the effects of chemicals on PPARG-dependent J.K. Hartman et al. Toxicology and Applied Pharmacology 355 (2018) 112-126 adipocyte differentiation (Foley et al., 2015; Foley et al., 2017) . Here the assay was modified to interrogate suspected glucocorticoid receptor agonists. Complete differentiation of the adipocyte stem cells in vitro is achieved with an eight-day repeat dosing strategy using a differentiation hormone cocktail (10 μg/mL insulin, 200 μM IBMX, 1 μM rosiglitazone, and 20 nM dexamethasone). Each of these chemicals activates a critical transcriptional event in the adipocyte differentiation program (Fig. 1) . To determine whether the original assay design could be modified to assess the effects of unknown compounds on the glucocorticoid receptor, the adipose stem cells were treated with a priming cocktail that contains only rosi, IBMX, and insulin. In the naive system (Sup. Fig. 1A ) or in the presence of the priming cocktail (Sup. Fig. 1B) , the adipose stem cells fail to differentiate or accumulate neutral lipids. In contrast, hASCs cultured in priming cocktail with a 10-point DEX concentration curve displayed a robust, concentration-dependent increase in lipid accumulation (Sup. Fig. 1E ), demonstrating that GRmediated adipogenesis can be faithfully assessed in the modified assay.
3.2. Evaluating ToxCast prioritized chemicals in a phenotypic assay for adipogenesis
Test chemical prioritization
To identify chemicals with potential GR-dependent adipogenic activity, we employed a published prioritization schema . The Toxicological Priority Index (ToxPi) model examined data from 1858 chemicals tested in 821 high-throughput assays for a variety of endpoints including cytotoxicity, cell growth, receptor binding, and gene activity as part of Phase I and II of the USEPA ToxCast program. Collectively, perturbation of these endpoints is referred to as bioactivity and serves as one source of hazard identification for associated adverse endpoints. These data were used to predict chemicals likely to affect various endocrine pathways, including the GR pathway. One assay for GR-specific binding (NVS_NR_hGR), three assays for GR-specific agonism (ATG_GRE_CIS_up, ATG_GR_TRANS_up, Tox21_GR_-BLA_Agonist_Ratio), one assay for GR-Specific antagonism (Tox21_GR_BLA_Antagonist_ratio), and two assays for GR-independent associated function (NVS_ENZ_hSGK1, NVS_GPCR_rCRF) were included in the ToxPi model GR slice to evaluate potential for perturbing the GR pathway . The ToxPi score is generated using an algorithm that weights key features such as a chemical's bioactivity profiles, toxicity pathways, and dose estimates (Reif et al., 2010; Filer et al., 2014) . ToxPi values close to one translate to higher potency, higher predicted bioavailability, or greater pathway changes, and values closer to zero translate to lower potency, lower bioavailability, and fewer pathway changes (Reif et al., 2010; Filer et al., 2014) . Note that ToxPi values are calculated independently from ToxCast hit calling, so it is possible to have ToxPi scores for compounds that tested negative in ToxCast (Table 1 ). The top 20 ranked chemicals (z > 0.01) for GR activity were prioritized for evaluation with our phenotypic adipogenesis assay (Table 1) , except for diphenylmercury(II), which was excluded due to potential human and environmental hazards. Tolylfluanid was also included in the test compounds. While tolylfluanid was inactive in the ToxCast assays for GR activity and was not prioritized by ToxPi, it has been shown to promote adipogenesis via the glucocorticoid receptor in murine 3T3-L1 cells (Sargis et al., 2010; Neel et al., 2013) . A summary of the ToxPi prioritization score and the most current data on hit-calls from the ToxCast assays is provided in Table 1 .
The 20 compounds in Table 1 were tested for concentration-response in our multiplexed adipogenesis assays that simultaneously measure three distinct markers of adipocyte differentiation: lipid accumulation (RLA), FABP4 protein expression, and adipokine secretion (Fig. 1) , as well as lactate dehydrogenase (LDH) and total cell counts for acute and chronic cytotoxicity, respectively. Hit calls for each test compound were evaluated on a composite score of all completed endpoints, rather than identifying hits based on a single endpoint.
Cytotoxicity
Each of the 19 prioritized test compounds and tolylfluanid, were screened in concentration-response format in the adipogenesis assay. None of the compounds caused significant acute cytotoxicity, as measured by an increase in LDH after two days of treatment (data not shown). However, four of the chemicals (mifepristone, cyproterone acetate, hydroxyprogesterone caproate, and tolylfluanid) did lead to chronic cytotoxicity at high concentrations. Concentration points for each test chemical promoting decreased relative cell counts at 8 days (> 10% decrease in cell count relative to the vehicle control) were excluded from all downstream analyses (Sup. Fig. 3 ). Individual chemical data for all endpoints are provided in the Supplemental Materials (Sup. Fig. 2-5 ).
Relative lipid accumulation
As shown in Fig. 2 by representative curves, the compounds generally grouped into three patterns of response: a strong concentrationdependent RLA ( Fig. 2A, D) , weak RLA only at the highest concentrations (Fig. 2B, E) , and no RLA at any tested concentration (Fig. 2C, F ) (see Sup. Fig. 2 for individual curves) . The area under the curve (AUC) for all non-cytotoxic concentrations was calculated for each chemical and used to rank order compounds by bioactivity. Because it integrates efficacy and potency into a single metric, AUC provides a valuable summary for ranking compound bioactivity for prioritization applications (Rotroff et al., 2014; Judson et al., 2015) . Here, higher AUC values correspond to more bioactivity, which translates to a larger response and/or a response at a lower concentration. As shown in Fig. 2G , 5/20 chemicals induced relative lipid accumulation with an AUC above 1.5. Dexamethasone, melengestrol acetate, triamcinolone, corticosterone, and bis(2-ethylhexyl) tetrabromophthalate were active in the Tox21 GR agonist assay. Of these, all except for bis(2-ethylhexyl) tetrabromophthalate were also active in our assay. Prednisone, which was identified as a GR antagonist in Tox21, demonstrated a strong positive agonist response with an AUC of 3.5. Interestingly, four of the compounds, 17α-hydroxyprogesterone, cyproterone acetate, hydroxyprogesterone caproate, and norethindrone, were all predicted to be GR-antagonists by Tox21, yet all four were weakly positive hits for lipid accumulation (AUC 0.75-1.0), while the remaining eleven compounds demonstrated little to no response (AUC < 0.75).
FABP4 protein expression
Fatty acid binding protein 4 (FABP4) is a marker of both early and late adipogenesis (Moseti et al., 2016) . Immunofluorescence was used to quantitatively evaluate FABP4 expression (as % FABP4 positive cells) together with RLA. As previously noted, the chemicals generally grouped into 3 classes. Representative compounds are shown in Fig. 3 , and all individual data plots are found in Supplemental Fig. 4 . The strong agonists caused concentration-dependent increases in FABP4+ cells at relatively low concentrations (Fig. 3A, D) , whereas the weaker agonists showed minimal increases in FABP4+ cells at the higher concentrations (Fig. 3B, E) . Those chemicals that did not induce RLA also showed no increase in FABP4+ cells (Fig. 3C, F) . As described above, we determined the AUC for FABP4 expression at all non-cytotoxic concentrations and rank-ordered the compounds by bioactivity (Fig. 3G) . The 5 chemicals with the most potent RLA response were also the 5 highest responders for FABP4 expression (AUC > 1.0). While the weak RLA-inducing chemicals induced a slight increase in FABP4 above the vehicle control, there was a clear difference in the ability of the strong-RLA inducing compounds to cause upregulation of adipocyte specific gene expression.
Adipokine secretion
Fully differentiated mature adipocytes secrete cytokine proteins (adipokines) that mediate inflammation and insulin resistance (Kwon and Pessin, 2013) , including leptin, IL-6, and TNF-α. Adiponectin is exclusively secreted from adipose tissue and is important for insulin J.K. Hartman et al. Toxicology and Applied Pharmacology 355 (2018) 112-126 sensitivity, fatty acid oxidation, and glucose uptake (Coelho et al., 2013) . Adiponectin secretion into the culture media was assessed as a marker of functional differentiation in the same samples evaluated for RLA and FABP4. Representative compounds for the strong RLA, weak RLA and no RLA response groups are shown in Fig. 4 (individual curves in Sup. Fig. 5 ). Strong RLA inducers also induced a dramatic concentration-dependent increase in adiponectin secretion relative to the vehicle control (Fig. 4A) . In contrast, neither the weakly RLA-inducing (Fig. 4B) nor the non-RLA inducing (Fig. 4C ) compounds induced adiponectin secretion at any concentration. The AUC for adiponectin secretion at all non-cytotoxic concentrations was used to rank order compounds by bioactivity (Fig. 4D) . As with the primary RLA and FABP4 assay, the 5 most potent chemicals were also the 5 highest for adiponectin secretion (AUC > 1.0). Interestingly, in contrast to the other two endpoints, adiponectin secretion was clearly restricted to the top five compounds, with the remaining compounds inducing almost no measurable adiponectin (AUC < 1.0). This likely reflects the fact that adiponectin secretion is a hallmark of fully differentiated adipocytes. Importantly, all five of the strongest agonists identified in the RLA assay were also hits for FABP4 expression and adiponectin secretion, suggesting that they are true positives that can induce adipocyte differentiation.
Determination of GR-dependence of adipogenesis response
The weight of evidence from the primary lipid accumulation endpoint and the protein expression and adipokine secretion assays strongly suggests that at least a subset of the prioritized compounds can in fact induce adipogenesis in a GR-dependent manner. To confirm that the adipocyte differentiation observed in response to these chemicals was dependent on activation of the GR pathway, we developed a novel competition assay using the known GR-antagonist mifepristone (RU-486). Mifepristone has a higher affinity for the glucocorticoid receptor than dexamethasone and should therefore be able to inhibit even the most potent agonists (Gagne et al., 1985) . First, we examined whether mifepristone could inhibit lipid accumulation in the presence of a concentration response curve (100 μM-0.01 μM) of dexamethasone.
Mifepristone inhibited dexamethasone induced RLA at all tested concentrations (Fig. 5A) , and even at concentrations as high as 1 μM DEX, mifepristone reduced RLA to baseline levels. Cells treated with 100 μM DEX were highly positive for AdipoRed in the absence of mifepristone (Fig. 5B) , whereas in the presence of 10 μM mifepristone, the size and frequency of AdipoRed lipid droplets was markedly reduced (Fig. 5C ).
This co-treatment approach was used to screen nine compounds that showed a lipid accumulation response in the primary RLA screen (dexamethasone, triamcinolone, prednisone, melengestrol acetate, corticosterone, 17alpha-hydroxyprogesterone, cyproterone acetate, hydroxyprogesterone caproate, and norethindrone), as well as two compounds that did not show a response in any of the endpoint assays (diethyl sulfate and dicamba). The hASCs were treated with either a concentration response curve (100 μM-0.01 μM) of the candidate compound alone or in combination with mifepristone (10 μM). At the end of the eight day treatment period, RLA and chronic cytotoxicity were assessed as previously described. The combination of the compounds did not cause any additional cytotoxicity than had been observed with the compounds alone (data not shown). Individual data are provided in the Supplemental Materials (Sup. Fig. 6 ) and representative chemicals are shown in Fig. 5D -F. Mifepristone treatment reduced the RLA induced by the 5 strong RLA inducers in a concentration-dependent manner (Fig. 5D ). In contrast, mifepristone treatment had no effect on the weaker RLA inducing chemicals (Fig. 5E ) and the non-RLA inducing chemicals (Fig. 5F ). Mifepristone had no effect on the RLA that was observed with any of the four weak compounds, suggesting that the observed effects on adipogenesis were not GR-dependent.
Evaluating GR-mediated antagonism of human adipogenesis
Relative lipid accumulation
While our previous efforts have primarily focused on agonism of suspected endocrine disrupting chemicals, it was clear from the ToxCast activities listed in Table 1 that many of the compounds were predicted to be antagonists of the glucocorticoid receptor. In fact, all four of the weak RLA agonists and six of the negative chemicals were active in the Tox21 GR receptor-binding antagonism assay. Therefore, if 10/20 compounds tested were not predicted to act as agonists, by not testing antagonism, we do not get the full picture of the effects of these compounds on adipogenesis. To demonstrate that antagonism could also be tested in this assay, the hASCs were treated with the full differentiation cocktail (PCM) in the presence of a concentration curve of either the GR-antagonist mifepristone (Fig. 6A) or the PPARG antagonist GW9662 (Fig. 6B ). Both mifepristone and GW9662 markedly decreased RLA in a concentration-dependent manner, although both compounds were cytotoxic at the highest concentration tested (100 μM). This modified version of the adipogenesis assay was used to test 19 of the test compounds with a 10-point concentration curve. DEX was not tested in this assay, because it is required for the full differentiation cocktail. Representative data are shown in Fig. 6C -F, and individual response curves are shown in Supplemental Fig. 7 . As previously described, cytotoxicity was assessed by cell counts (Sup. Fig. 8 ). As expected, treatment of the hASCs with the five strongest RLA agonists identified above had no effect on RLA (representative graph, Fig. 6C ). In contrast, the four previously identified weak agonists, such as 17α-hydroxyprogesterone, caused a concentration-dependent decrease in RLA (Fig. 6D) . Of the eleven compounds that had no effects on lipid accumulation in the agonism assay, four strongly inhibited RLA (representative graph, Fig. 6E ), while the remaining seven did not affect RLA at any concentration tested (representative graph, Fig. 6F ). To determine bioactivity for the antagonism assay, the AUC for each concentration-response was calculated (Fig. 6G) . The four most active chemicals from the screen were mifepristone, norgestrel, cyproterone acetate, and spironolactone (AUC > 0.75). Interestingly, both norgestrel and cyproterone acetate were weakly active in our primary lipid accumulation screen, but also inhibited RLA in the antagonism screen. In the agonism assay, cyproterone acetate was cytotoxic at 100 μM, which was not the case in the antagonism assay (data not shown). Of the 10 predicted antagonists, 8/10 inhibited RLA (AUC > 0). Neither prednisone nor 3,5,3′-triiodothyronine (T3) had any effect on RLA, and prednisone had previously shown to be an agonist in the primary Fig. 2 . Relative lipid accumulation in response to treatment with GR-bioactive compounds. The hASCs were treated with the priming cocktail in the presence of the test compounds (n = 3, SEM). The chemicals grouped into three categories: strong concentration-dependent RLA (A), weak RLA at the highest concentrations (B), or no RLA at any concentration (C). (D-F) Cells were stained with AdipoRed (lipids, green) and Hoescht (nuclei, blue), 20× Representative images shown demonstrate strong RLA (triamcinolone, D), weak RLA (17α-hydroxyprogesterone, E) or no response (diethyl sulfate, F) (100 μM concentration shown). (G) The AUC for each relative lipid accumulation concentration curve was calculated (at all non-cytotoxic concentrations), and the AUC results were rank-ordered for bioactivity. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) J.K. Hartman et al. Toxicology and Applied Pharmacology 355 (2018) 112-126 screen.
FABP4 protein expression and adipokine secretion
To confirm that adipogenesis was inhibited in the presence of the antagonists, we performed the previously described multiplexed assays for FABP4 protein expression and adipokine secretion. Both mifepristone (Fig. 7A) and GW9662 (Fig. 7B) reduced the percent FABP4+ cells in a concentration-dependent manner. Similarly, adiponectin secretion was also reduced to baseline levels at the highest concentrations by both antagonists (Fig. 7C, D) .
FABP4 expression and adiponectin secretion were analyzed simultaneously with RLA to confirm that the decrease in RLA was due to a lack of differentiation and not simply a block in lipid accumulation (individual graphs in Supplemental Figs. 9-10). As above, we determined the AUC for FABP4 expression (Fig. 7E) , as well as the AUC for adiponectin secretion (Fig. 7F) at all non-cytotoxic concentrations and rank ordered them for bioactivity. As with the RLA assay, mifepristone was the most potent inhibitor of both FABP4 expression and adiponectin secretion. For FABP4, 11/19 chemicals scored above the baseline (AUC > 0), and 15/19 chemicals scored above the baseline (AUC > 0) for adiponectin secretion.
Defining GR-mediated bioactivity across assay endpoints
As a first line comparison of the various assays, we summarized all of the data by AUC for each endpoint or as an aggregate agonist or antagonist score and compared to ToxCast results (Fig. 8, Sup . Table 1) . Aggregate AUC was calculated as the unweighted arithmetic mean of the AUC agonism or antagonism endpoints (RLA, FABP4, and adiponectin). The compounds generally cluster by biological response (agonism, antagonism, inactive) irrespective of assay system. However, a few notable exceptions exist. Bis(2-ethylhexyl) tetrabromophthalate was active in the ToxCast GR agonist and GR ligand binding assays but activity was not detected in either our agonism or antagonism Fig. 3 . Differentiation of hASCs in response to GR-bioactive compounds. The hASCs were treated with the priming cocktail in the presence of each of the 20 test chemicals (n = 3, SEM). After the eight day treatment period, the cells were fixed and stained for FABP4 by immunofluorescence. (A-C) The FABP4+ cells were quantitated using the Opera Phenix Harmony software and the data are presented as FABP4+ cells/DAPI+ total nuclei. (D-F) Representative images of the immunofluorescence staining for FABP4 confirm the quantitation data for triamcinolone (D), 17α-hydroxyprogesterone (E), and diethyl sulfate (F) (100 μM, FABP4 in red and DAPI stained nuclei in blue, 20×). (G) The AUC for each FABP4 concentration curve was calculated (at all non-cytotoxic concentrations), and the AUC results were rank-ordered for bioactivity. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) J.K. Hartman et al. Toxicology and Applied Pharmacology 355 (2018) 112-126 endpoints. Prednisone was identified as a GR-antagonist in ToxCast but showed strong agonist activity in all agonist endpoints of the phenotypic adipogenesis assay. This agonist activity was verified as GR-dependent when co-treated with prednisone and mifepristone (the GR inhibitor). Finally, the thyroid hormone 3,5,3′-triiodothyronine showed interesting behavior. Despite demonstrated GR antagonist activity in ToxCast, it showed no activity in the current antagonism endpoints and negligible activity in the adiponectin and FABP4 orthogonal assays for agonism, but without a concurrent increase in RLA. Together, the potency and efficacy (AUC) of the tested compounds across the three agonism and three antagonism endpoints provides a composite measure of glucocorticoid bioactivity. To evaluate whether the AUC could be used to categorize the compounds, we plotted the aggregate agonism AUC against the aggregate antagonism AUC for each chemical (Fig. 9) . Using this graphical approach, a clear spectrum of biological activity for each chemical can be seen, with the inactive chemicals clustering around the origin. To determine a true hit, we calculated the mean of the clustered inactive compounds, and any compound that was greater than three standard deviations from the mean was considered a hit. From this data, we identified 5/20 compounds as GR agonists capable of supporting adipocyte differentiation (aggregate agonism AUC > 0.81): triamcinolone, dexamethasone, melengestrol acetate, corticosterone and prednisone. Eight compounds were identified as GR antagonists capable of prohibiting hormonemediated adipocyte differentiation (aggregate antagonism AUC > 0.20): 17-alpha hydroxyprogesterone, hydroxyprogesterone caproate, norethindrone, cyproterone acetate, norgestrel, mifepristone, thiocarbazide, and spironolactone. The remaining 7 compounds were considered inactive in our phenotypic assays.
Evaluating active concentrations of identified agonists and antagonists
For each of the five GR agonists and eight GR antagonists we fit Hill functions to each relevant endpoint (Sup. Fig. 11 , Sup. Table 1 ). The concentration response curves were evaluated to define the effective concentrations (AC 50 , concentration at 50% activity). For agonists (Fig. 10A) , compound potency was consistent across the three phenotypic endpoints; only one compound (melengestrol acetate) had AC 50 values that varied more than one order of magnitude. Furthermore, phenotypic endpoint-derived potencies were similar to potencies of the same agonists previously reported in the Tox21 GR agonism assay, which uses a β-lactamase reporter expressed in HeLa cells to assess glucocorticoid activity. On an absolute concentration basis, the antagonists were less potent than the agonists (Fig. 10B) . Interestingly, we observed a weak relationship between AUC and AC 50 for both agonism and antagonism, reflecting the considerable variability in the maximal response of the compounds across different endpoints.
Comparing in vitro potency to human exposures
Since the active compounds were all pharmaceuticals, we could take advantage of clinical data to evaluate the predictivity of our model. Of the 5 agonists, 4 are human synthetic or endogenous glucocorticoids, which target the GR receptor (corticosterone, prednisone, dexamethasone, triamcinolone). Several of the antagonists are human therapeutics that target GR (mifepristone) and/or other hormone pathways, including progesterone receptor and estrogen receptor. Human blood concentrations associated with therapeutic doses (Cmax) were compared to the in vitro potency data (Fig. 10, open squares) . For the compounds designed specifically to target the GR pathway, the active concentrations in vitro were below therapeutic levels (prednisone, dexamethasone, triamcinolone), indicating that the adipogenesis assay is sufficiently sensitive to predict human GR-mediated responses. Therapeutic levels of anti-androgen cyproterone acetate are below the in vitro active concentrations for the phenotypic adipogenesis endpoints, but above the active concentrations predicted by the Tox21 β-lactamase reporter assay. For compounds that are designed to target other hormone pathways, in vitro active concentrations were well above the therapeutic concentrations (17a-hydroxyprogesterone, norethindrone, spironolactone). This is as would be expected, as the therapeutic doses are likely designed to limit potential off-target effects via the GR pathway. The ability of this phenotypic model to distinguish between active and inactive concentrations of these pharmaceutical compounds supports the utility of these assays to predict the bioactive concentrations in the human population. We used in vitro to in vivo extrapolation (IVIVE) to convert exposure predictions from ExpoCast to internal blood concentrations (USEPA Chemistry Dashboard, 2017). Predicted steady state blood concentrations (Css) based on these exposure estimates are shown versus the in vitro activity data (Fig. 10 , open diamonds, Sup. Table 2 ). These results demonstrate how phenotypic cell-based assays can contribute to the risk-based decision-making process by identifying potentially bioactive compounds and estimating their potency through in vitro-to-in vivo extrapolation.
Discussion
Systematic design of biologically relevant phenotypic cell-based assays
As testing for human risk assessment continues to move away from expensive, time consuming in vivo toxicity experiments, it has become increasingly important that suitable in vitro alternatives are developed that can be used for determining points of departure. These so-called fitfor-purpose assays must be 1) human relevant, 2) performed in biologically faithful systems that recapitulate key endpoints, and 3) capable of producing concentration-response data for risk assessment. Although there are several useful mouse models of adipogenesis, including the mouse 3T3-L1 and the 3T3-F442A cell lines that are derived from mouse fibroblasts, there are species differences that would not be accurately addressed in rodent cells (Ruiz-Ojeda et al., 2016) . Using a systematic pathway approach that considers the biologically relevant endpoints and mechanisms of adipogenesis, we have developed a human-relevant in vitro assay for assessing the effects of purported endocrine disrupting chemicals on adipogenesis. Because this assay can recapitulate the molecular and cellular mechanisms of adipogenesis, it is sensitive to perturbations in those pathways. We previously reported on the use of this primary human adipose-derived stem cell in vitro assay for determining the effects of ToxCast prioritized chemicals on PPARG signaling. Here, we have modified the existing assay to focus on another key nuclear receptor, the glucocorticoid receptor.
Twenty chemicals with ToxCast data and prioritized for GR activity in the published ToxPi approach were tested in a concentration-response manner in this phenotypic assay. Of the 20 chemicals, 5 were predicted to be GR agonists via ToxCast and 4 of these induced GR-dependent adipogenesis in the primary human adipogenesis assay. Interestingly, all four of these chemicals are natural or synthetic steroid hormones. Corticosterone is an endogenous glucocorticoid and is the primary glucocorticoid in rodents, but a minor glucocorticoid in humans (McCormick et al., 2017) . Dexamethasone and triamcinolone are synthetic corticosteroids used to treat a variety of inflammatory and immune disorders, including eczema, rheumatoid arthritis, and asthma (Bristol-Myers Squibb Company, 2011; Fresenius Kabi USA, 2014) . Melengestrol acetate is a steroid progestin that is commonly used as a feed additive for cattle to promote growth, but is not currently approved for use in humans (Stephany, 2010) . Since these compounds are in fact hormones designed to modulate endocrine function, it is not surprising that they were able to alter the GR-dependent adipocyte responses. The importance of using a fit-for-purpose biologically relevant assay for compound screening to aid in risk assessment, rather than relying solely on high-throughput screening, is highlighted with prednisone. Prednisone, a synthetic glucocorticoid used to treat inflammatory diseases, demonstrated GR antagonism in the Tox21 transactivation assay (Horizon Pharma, 2012) . However, in our phenotypic adipogenesis assay, prednisone was a strong agonist, with no antagonism activity. Interestingly, prednisolone, which is the bioactivated form of prednisone (Tomlinson et al., 2007; Raza et al., 2010) was an agonist in the Tox21 reporter assay. In vivo, the glucocorticoids cortisone and 11-dehydrocorticosterone are bioactivated to cortisol and corticosterone by 11-oxoreductase activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which is abundantly expressed in both liver and adipose tissue (Seckl et al., 2004; Draper and Stewart, 2005; Tomlinson et al., 2007; Esteves et al., 2014) . Therefore, it seemed plausible that prednisone was bioactivated to prednisolone in the adipocytes, which promoted agonist activity. While the undifferentiated hASCs do not express 11β-HSD1, hASCs in the priming cocktail begin to upregulate the enzyme, and the fully differentiated adipocytes express higher levels of 11β-HSD1 than the hASCs in the primed cocktail (Sup. Fig. 12A-C) . To test whether bioactivation of prednisone by 11β-HSD1 was plausible in our system, 11β-HSD1 was inhibited using a known pharmacologic inhibitor (PF915275) in the presence or absence of prednisone in our GR-agonism assay. Inhibition of 11β-HSD1 reduced, but did not fully prevent, relative lipid accumulation in response to prednisone. While the role of adipocytes in systemic toxicant biotransformation is unclear, adipocytes are highly metabolically active in vivo and express a range of xenobiotic metabolizing enzymes in addition to 11β-HSD1, including cytochrome p450 isozymes (CYP1B1, CYP2Bs, CYP3As), paraoxonases, carboxylesterases, and several isozymes of UDP-glucuronosyltransferases, which could affect the activity of chemicals within the fat depot (Yoshinari et al., 2004; Draganov, 2007; Ohno and Nakajin, 2009; Ellero et al., 2010) . The role of metabolism in the response of these adipocytes in the hASC assay bears further investigation; it is an intriguing possibility that (1) these differentiated adipocytes may be metabolically active and (2) bioactivation of prednisone in the in vitro assay by the adipocytes could lead to different results than those seen in the high throughput assays (Sup. Fig. 6 . Antagonism of relative lipid accumulation by GR-bioactive chemicals. The hASCs were treated with the full differentiation cocktail (PCM) and a concentration-curve of the GR-antagonist mifepristone (A) or the PPARG antagonist GW9662 (B) and RLA was determined as described. (C-F) To screen the chemicals, hASCs were treated with the PCM in the presence of a 10-point half-log concentration curve of the test compound (n = 4, SEM). (G) The AUC for each RLA concentration curve was calculated (at all non-cytotoxic concentrations), and the results were rank-ordered for bioactivity. Fig. 12D ).
Bis(2-ethylhexyl) tetrabromophthalate (TBPH) was the only chemical identified as an agonist in ToxCast that did not demonstrate GR activity in the adipogenesis assay and was also the only environmental chemical. TBPH is an industrial flame retardant and plasticizer commonly used in PVC coating (Xiang et al., 2017) . In the Tox21 agonist assay, which is a HeLa cell-based reporter assay that measures GR transactivation, TBPH had an AC 50 of 44.2 μM, which is within the range of concentrations tested here. Literature, however, does not show clear support for TBPH GR agonism. A previous study with a reporter gene assay demonstrated that TBPH binds GR but has anti-glucocorticoid activity (Klopcic et al., 2016) . TBPH treatment in mouse 3T3-L1 cells caused concentration-dependent lipid accumulation (up to 20 μM), but no change in adipogenic gene expression (Tung et al., 2017) . The disparity in the data from ToxCast GR assays and the phenotypic adipogenesis assays suggests that while TBPH is able to bind GR, it is not able to induce the full adipocyte differentiation response. These data demonstrate that the effects of a given chemical on a biological process are likely to be both concentration and context dependent.
In addition to assessing GR-dependent agonism, the hASC assay could be modified to determine GR-dependent antagonism. Because many of the ToxCast prioritized chemicals were in fact predicted to be antagonists, it was important to screen all the chemicals through the antagonism assay. Of the ten Tox21 predicted antagonists, 7/10 predicted antagonists scored as positive hits. Prednisone, equilin, and T3 did not cause any GR-dependent antagonism on adipogenesis in the Fig. 7 . Antagonism of adipocyte differentiation by GR-bioactive chemicals. The hASCs were treated with the full differentiation cocktail (PCM) and a concentrationcurve of the GR-antagonist mifepristone (A, C) or the PPARG antagonist GW9662 (B, D) and percent FABP4+ cells and adiponectin secretion were determined as described. To screen the chemicals, hASCs were treated with the PCM in the presence of a 10-point half-log concentration curve of the test compound (n = 4, SEM) and FABP4 and adiponectin were analyzed. (E) The AUC for each FABP4 concentration curve was calculated (at any non-cytotoxic concentration) and the results were rank-ordered for bioactivity. (F) The AUC for each adiponectin concentration curve was calculated (at all non-cytotoxic concentrations), and the results were rank-ordered for bioactivity.
J.K. Hartman et al. Toxicology and Applied Pharmacology 355 (2018) 112-126 hASC assay, despite being predicted to bind GR and have antagonism activity. In contrast, thiocarbazide, which was not predicted to be a GRinteracting chemical in any of the ToxCast assays, did cause a modest decrease in RLA, as well as in FABP4 expression and adiponectin secretion. Thiocarbazide is typically used for staining carbohydrates for electron microscopy (Leser et al., 2009) . It is unclear why it would have an effect on GR-mediated adipogenesis, though the lack of interaction with GR suggests a receptor independent mechanism that would not be predicted in the high throughput models. It is conceivable that these chemicals could have GR-dependent effects on other biological pathways or cell types, but these data demonstrate the importance of confirming ToxCast prioritized chemicals' effects on the specific tissues of interest.
One interesting observation was that several of the GR antagonists were weakly positive in the agonist RLA assay (Fig. 8) . However, they did not induce responses in the orthogonal assays. Furthermore, of these four chemicals, none were found to be GR-dependent in the coagonist/antagonist assay, suggesting that the lipid response may occur through off target effects. Importantly, the multiplexed nature of this (Figs. 6, 7 ) and the Tox21 GR Antagonist assay. One of the eight antagonists, thiocarbazide, had no endpoints meeting both the AUC and Hill model criteria for inclusion. Here, horizontal position of the marker denotes the AC 50 of the Hill function fit to the concentration response (Sup. Fig. 11 ). Marker size reflects the AUC of the concentration response for each endpoint (Fig. 9 , Sup. Table 1 ). Tox21 GR Agonist assay is included for reference (purple maker). Markers are omitted where AUC < 0 or a Hill function was not successfully fit (see Materials and Methods). Open square shaped markers indicate plasma concentrations (Cmax) from human clinical data at therapeutic doses and open diamond shaped markers indicate steady state blood concentrations (Css) calculated from ExpoCast median environmental exposure estimates using IVIVE (see Methods). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) assay can help avoid misclassification of compounds. Using the aggregate AUC scores instead of the individual assay endpoints effectively discriminates between true agonists (dexamethasone, prednisone, corticosterone, melengestrol acetate, and triamcinolone) and those compounds with GR-independent effects on lipid accumulation (17α-hydroxyprogesterone, cyproterone acetate, hydroxyprogesterone caproate, and norethindrone). Taken together, these data highlight the importance of using biologically relevant, cell-based fit-for-purpose assays to further screen chemicals that have been prioritized in high throughput assays to determine the phenotypic and directional effects (i.e. agonism or antagonism) of unknown chemicals on biological pathways.
Using a biologically relevant model to predict chemical potency
Beyond the role of in vitro models in high throughput screening (HTS), mode of action analyses, and chemical prioritization, we contend that human cell-based models that are capable of recapitulating key biological pathways can ultimately be used to help provide a weight of evidence for supporting decisions about risk to the human population. For this to be successful, in vitro assays must predict not only the potential hazard (i.e., phenotype), but also the concentrationresponse. We tested the ability of the adipogenesis model to identify active chemical concentrations. When compared to therapeutic blood levels, the assay was able to predict concentrations at which GR activity would be expected for natural and synthetic glucocorticoids. The assay also predicted the absence of GR activity at therapeutic concentrations for the compounds targeting other hormone pathways. These predictions are in keeping with what would be expected for the therapeutic use of the compounds, as doses would be selected to specifically target the pathway of interest, while avoiding off-target disruption of the glucocorticoid pathway. The favorable comparison of the in vitro predicted potency with clinical data supports the potential utility of these assays for predicting human response. We also used IVIVE to predict steady state blood concentrations (Css) associated with predicted environmental exposures in ExpoCast for 4/5 agonists and 4/8 antagonists. Most of the predicted exposures have estimated Css values well below our estimated bioactive concentrations. As the exposure models are designed primarily for industrial and environmental chemicals, it is not clear how applicable predictions are for pharmaceuticals. Given the clear role of the GR pathway in reproductive and endocrine health, there is clearly a need for better refinement of the exposure estimates for these compounds.
Conclusions
Taken together, these data clearly demonstrate that while highthroughput approaches to toxicity assessment can provide useful data for prioritizing the bioactivity of a large number of chemicals, it is still necessary to test these compounds in more biologically relevant assays. In this case, the ability to leverage the information from multiple orthogonal endpoints to predict agonist or antagonist activity strengthens the predictive power of the assay in terms of identifying compounds that can induce not only an early ligand binding event, but a true phenotypic response associated with chemical toxicity. By building the assay around the biological pathway of interest, ensuring that the system maintains the key biological factors that drive phenotypic responses, and framing the chemical responses' in the context of human therapeutic or environmental exposures, we also increase confidence in the interpretation of the resulting data. Hundreds of ToxCast chemicals were found to interact with the GR pathway (in Tox21 reporter and Novascreen binding assays). While the compounds evaluated in this paper were primarily pharmaceuticals, the biological and species relevance of the system and the consistency of predicted potencies with human data, indicate that extension of this assay to the greater chemical landscape could be a worthwhile endeavor.
Hazard characterization and prioritization are key components of risk assessment. Existing screening paradigms at the US EPA, including the future roadmap of chemical testing in the ToxCast/Tox21 programs, utilize a tiered approach to hazard characterization that are reliant on high throughput screening to initially flag potential bioactivity across a high volume of chemical substances. Alternative organotypic and microphysiological in vitro systems are becoming an increasingly important aspect of orthogonal follow up. Though these systems lack the throughput capacity of HTS, they may provide increased comprehension of the toxicodynamics in more human relevant phenotypic models. In addition, understanding how human exposures relate to toxicodynamics requires bioactivity estimates that are closely tied to tissue-specific phenotypes of interest. The data presented in this study provide a case study for how those bioactivity-exposure margins may be interpreted from a risk assessment standpoint using an in vitro organotypic model with a human relevant tissue endpoint. More demonstrations of this paradigm are needed to define the utility of an in vitro centric approach for regulatory decisions as the field moves toward non-animal methods.
